Document is current
Any future updates will be listed below
-
Authors
Gazeau, Nicolas https://orcid.org/0000-0003-3449-6676
Beauvais, David
Tilmont, Rémi https://orcid.org/0000-0003-1739-2162
Srour, Micha https://orcid.org/0000-0002-8519-4187
Ferrant, Emmanuelle
Safar, Violaine
Fouillet, Ludovic
Flandrin-Gresta, Pascale https://orcid.org/0000-0001-6258-7028
Gower, Nicolas
Chauvet, Paul https://orcid.org/0000-0001-6326-9283
Duployez, Nicolas https://orcid.org/0000-0002-3927-1022
Podvin, Benjamin
Demaret, Julie
Huet, Sarah https://orcid.org/0000-0002-3408-2783
Sujobert, Pierre https://orcid.org/0000-0003-1724-4792
Ghesquières, Hervé
Damaj, Gandhi https://orcid.org/0000-0002-4689-3882
Bachy, Emmanuel
Morschhauser, Franck
Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
Heiblig, Maël
Sesques, Pierre
- License Information
-
More Information
Article History
Received: 4 January 2025
Revised: 9 March 2025
Accepted: 2 April 2025
First Online: 24 April 2025
Competing interests
: NGa, RT, MS, GD, NGo, LF, PFG, ND, BP, JD, SH, PS, HG, MH, PS have no COI. DB declares honorariua for Kite/Gilead and Novartis, EF declares consultancy for Astra Zeneca, Beigene, Janssen and honoraria for Astra Zeneca, Beigene, Janssen, Cilag, Abbvie, Gilead, VS declares consultancy for Kite/ Gilead, Beigene, BMS, Janssen and other from Janssen, EB declares consultancy, honoraria, and membership on an entity’s Board of Directors or advisory committees from AbbVie, Roche, and Takeda; research funding from Amgen; honoraria and membership on an entity’s Board of Directors or advisory committees from BeiGene and Incyte; honoraria, other personal fees, and research funding from Bristol Myers Squibb; consultancy and honoraria from Janssen; honoraria and other personal fees from Novartis and Pfizer; honoraria from ADC Therapeutics; and consultancy, honoraria, and other personal fees from Kite, a Gilead Company, FM declares consultancy, honoraria, and membership on an entity’s Board of Directors or advisory committees from Kite/Gilead Sciences, Bristol Myers Squibb, AbbVie, Epizyme, AstraZeneca, Novartis, and Genmab; consultancy and membership on an entity’s Board of Directors or advisory committees from Servier; consultancy, honoraria, and other payments for expert testimony and scientific lectures from Roche/Genentech; and honoraria from Chugai and Eisai, IYA declares honoraria from KITE, BMS, Novartis, Miltenyi Biomedecine.
